Last Updated on March 10, 2022 by GlobeNewsWire
PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will be included at the 2022 MDA Clinical & Scientific Conference, being held March 13-16, 2022 in Nashville, TN and virtually.
Oral Platform Presentation:
Wednesday, March 16, 12:10 p.m. CST
Abstract Title: Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory patients with Pompe disease: an open-label Phase I/II study (ATB200-02)
Presenter: Barry Byrne, MD, PhD, University of Florida Health, Gainesville, FL, U.S.A.
Location: Tennessee Ballroom
Abstract Title: Immunogenicity of cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset pompe disease: A phase III, randomized study (PROPEL)
Presenter: Tahseen Mozaffar, MD, University of California, Irvine, CA, U.S.A.
Location: Ryman Exhibit Hall B1-2, Poster #65Abstract Title: Living with Pompe disease in the UK: Characterizing the patient journey; burden on physical and emotional quality of life; and impact of COVID-19
Presenter: Derralynn Hughes, BMBCh, University College London, London, U.K.
The posters and presentation will be made available on the Amicus website following their respective presentations at the conference.
For more information on the 2022 MDA Clinical & Scientific Conference, please visit www.mdaconference.org.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow us on Twitter and LinkedIn.
Executive Director, Investor Relations
Head of Global Corporate Communications